| Name | Title | Contact Details |
|---|
Equipping Youth is a Cedar Rapids, IA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
St Agnes Home is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Infinity Rehab is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Infinity Rehab is based in Wilsonville, OR. You can find more information on Infinity Rehab at www.infinityrehab.com
Two things distinguish CHIA in our pursuit of improving the Massachusetts health care system: our public-interest perspective, and our unique data sets. Our perspective is rooted in our independence – our agenda and findings are not colored by the special interests of industry or politics – and in the talents and commitment of CHIA employees. CHIA`s mission is to be the agency of record for Massachusetts health care information, to responsibly steward sensitive and confidential data, and to objectively report reliable and meaningful information about the quality, affordability, utilization, access, and outcomes of the Massachusetts health care system. We pursue this mission in the public interest. This informs our objective perspective, and our commitment to serving a broad, diverse audience. We are a hub, connecting our products to policymakers, public and private payers and providers, employers, researchers, and the residents of Massachusetts. Our vision is a transparent health care system where reliable information provides common ground for improvement and empowers people and organizations to make informed decisions.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.